{"id":19328,"date":"2024-03-08T09:33:00","date_gmt":"2024-03-08T14:33:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-publie-son-form-10-k-americain-et-son-document-denregistrement-universel-2023\/"},"modified":"2024-03-08T10:07:27","modified_gmt":"2024-03-08T15:07:27","slug":"dbv-technologies-publie-son-form-10-k-americain-et-son-document-denregistrement-universel-2023","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-publie-son-form-10-k-americain-et-son-document-denregistrement-universel-2023\/","title":{"rendered":"DBV Technologies publie son \u00ab\u00a0Form 10-K\u00a0\u00bb am\u00e9ricain et son Document d\u2019Enregistrement Universel 2023"},"content":{"rendered":"<div class=\"pr-date-globe\">March 08, 2024 09:33 ET<\/div>\n<p align=\"right\">Montrouge, France, le 8 mars 2024<\/p>\n<p align=\"justify\"><strong>DBV Technologies publie son \u00ab&nbsp;Form 10-K&nbsp;\u00bb am\u00e9ricain et son Document d\u2019Enregistrement Universel 2023<\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext : DBV \u2013 ISIN&nbsp;: FR0010417345 &#8211; Nasdaq&nbsp;: DBVT), une soci\u00e9t\u00e9 biopharmaceutique au stade clinique &lpar;la \u00ab&nbsp;Soci\u00e9t\u00e9&nbsp;\u00bb), a annonc\u00e9 aujourd&rsquo;hui que son \u00ab&nbsp;Form 10-K&nbsp;\u00bb 2023 avait \u00e9t\u00e9 d\u00e9pos\u00e9 aupr\u00e8s de la Securities and Exchange Commission&nbsp;&lpar;\u00ab&nbsp;SEC&nbsp;\u00bb) aux Etats-Unis ainsi que son document d\u2019enregistrement universel 2023 &lpar;\u00ab&nbsp;DEU&nbsp;\u00bb), aupr\u00e8s de l\u2019Autorit\u00e9 des March\u00e9s Financiers &lpar;AMF) en France.<\/p>\n<p align=\"justify\">Le DEU 2023 int\u00e8gre notamment les informations suivantes : <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">Le Rapport Financier Annuel; <\/li>\n<li style=\"text-align:justify;\">Le Rapport de gestion;<\/li>\n<li style=\"text-align:justify;\">Le Rapport sur le Gouvernement d\u2019entreprise&nbsp;;<\/li>\n<li style=\"text-align:justify;\">Le Descriptif du Programme de Rachat d\u2019Actions.<\/li>\n<\/ul>\n<p align=\"justify\">Les documents peuvent \u00eatre consult\u00e9s sur le site internet de la Soci\u00e9t\u00e9 \u00e0 l\u2019adresse <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-n9Y1gb4KK2G8mUl5ZXYmeSFpkelh7HS5S0oF7uO0aTOYsFyO0CNMRf96373xXFxtUN3Rnvcz4AtFmnxIUOvfmsBz4Y4oCmXBPNfiOP3OgpoM00ve8lLf23adl37iBgR\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.dbv-technologies.com\">www.dbv-technologies.com<\/a> dans la section Investisseurs. Le DEU 2023 est \u00e9galement disponible sur le site internet de l\u2019AMF &lpar;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-n9Y1gb4KK2G8mUl5ZXYmUt71t1I7nZAmDvBt0kxtdyTt3fFTp4_YMITx1AfkrKyAX2u5nr_vhdXoOCS8zywVwVRJ_3yiopKotvAPCMRjHA=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.amf-france.org\">www.amf-france.org<\/a>), et le \u00ab&nbsp;Form 10-K&nbsp;\u00bb sur le site internet de la SEC &lpar;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-n9Y1gb4KK2G8mUl5ZXYmVuE4wX8mcr5kSOz1HV3tFrrVcXt7-ZEnxneBC7ohS0JDUu1zCvEAMye2j6LiYvGbQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.sec.gov\">www.sec.gov<\/a>). <\/p>\n<p align=\"justify\">Une version imprim\u00e9e de ces documents est \u00e9galement disponible sans frais au si\u00e8ge de la Soci\u00e9t\u00e9 \u00e0 l\u2019adresse suivante&nbsp;: 177-181 avenue Pierre Brossolette, 92120 Montrouge.<\/p>\n<p align=\"justify\"><strong>A propos de DBV Technologies&nbsp;<\/strong><br \/>DBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV se concentre actuellement sur l&rsquo;\u00e9tude de l&rsquo;utilisation de sa plateforme technologique exclusive, Viaskin\u2122, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l&rsquo;anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l&rsquo;immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT\u2122), la plateforme Viaskin est con\u00e7ue pour dispenser des quantit\u00e9s de microgrammes d&rsquo;un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L&rsquo;EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l&rsquo;allergie sous-jacente d&rsquo;un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l&rsquo;allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s&rsquo;est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d&rsquo;allergies alimentaires. Les programmes d&rsquo;allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec Viaskin Peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l&rsquo;arachide. Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Montrouge, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Basking Ridge, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Global Select Market &lpar;symbole : DBVT) Pour plus d\u2019informations, veuillez consulter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-n9Y1gb4KK2G8mUl5ZXYmUXiAZqtac7uc2xbz3pYmFskMxAhKSEp4H1AoDyD4eHI74-A0gLvShbtqepkWrPRGCGAdtZEnh_GHsAee1iFLlU=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.dbvtechnologies.com\">www.dbvtechnologies.com<\/a> et nous contacter sur X &lpar;anciennement Twitter) et LinkedIn.<\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>Katie Matthews<br \/>DBV&nbsp;Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CvD18rebom07mP6J-icvhcX3Soj0V8DhvpCqBj45WqRxkmCgqLKa8s5ezpYgDUUQRsZj95EqiXbVDciYwV9_HGrsLkFawYhrmjwMBYA64VfkW0z4oUD81OIAmsExJsOfu-IP4tVsXapm3WQAssOFWg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Aurora Krause<br \/>DBV&nbsp;Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OKW1TgQHMi341I3WTI7QbLKudUE86Ar6I6_BI70Qy9FtkbMdngJ0MhuTMQ8U1GLFBJ5K__WTKqrHs1cuQ0XJVAGcW2MHuswVN50cTA1uHgThuEUebIZccgLK59iA_UaQxGEBXsv6u38ZAM3uvut35A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"aurora.krause-ext@dbv-technologies.com\">aurora.krause-ext@dbv-technologies.com<\/a><\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZS-zxYspx4reVosGtz11Uv2x7cFvOt02WnVdbhOFBN-iiQrOsYU48NjkRFIa1nyycppVUIApHr5r3gJaUKwvCbh8uMMb9jg9JaLG6pSr3LRh4gGtiiP-rHJIc9-jyIkvATQ5M9gZ1nrtCG4GdJCHzwJxUy9eUewWLmAQOVa2aYE=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZWJiZDVhNTMtNDExZS00ZWI5LWIwZTctNmMzMTkwYTM5NWFmLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[47],"class_list":["post-19328","press_releases","type-press_releases","status-publish","hentry","press_release_type-amf-filing"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/19328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/19328\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=19328"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=19328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}